Guess which ASX All Ords insider just bought 50 million shares in their company

Some major insider buying has taken place. What does this mean?

| More on:
A man in a business suit whose face isn't shown hands over two australian hundred dollar notes from a pile of notes in his other hand to an outstretched hand of another person.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It can be useful for investors to keep an eye on which shares have experienced meaningful insider buying.

This is because insider buying is often regarded as a bullish indicator, as few people know a company and its intrinsic value better than its directors.

If they are buying, it could be a sign that they are confident in the direction the company is heading and see value in its shares.

With that in mind, let's take a look at one ASX All Ords stock that has reported some major insider buying this week.

Which ASX All Ords reported insider buying?

The company in question is clinical stage biotechnology company PYC Therapeutics Ltd (ASX: PYC).

According to a change of director's interests notice, the company's non-executive chair, Alan Tribe, just snapped up 50 million shares through an off-market transfer on 17 May. This increased Tribe's holding in PYC Therapeutics to approximately 1.537 billion shares.

The release reveals that the biotech's chair paid a total of $5.25 million for the shares. This equates to an average of 10.5 cents per share. This is in line with where the ASX All Ords stock is currently trading.

Should you invest?

One leading broker that would likely approve of this purchase is Bell Potter.

Earlier this week, the broker initiated coverage on the ASX All Ords stock with a speculative buy rating and 17 cents price target.

Based on its current share price, this implies a potential upside of 62% for investors over the next 12 months.

Commenting on its bullish view, the broker said:

PYC Therapeutics (PYC) is a clinical-stage biotech company harnessing its differentiated RNA drug development platform to treat rare inherited diseases. PYC is actively progressing three drug candidates through clinical development, each of which has first-in-class and/or best-in-class potential. In May 2024, PYC reported highly encouraging first clinical data for its lead drug candidate (called VP-001) in patients with a rare form of blinding eye disease, called retinitis pigmentosa type 11 (RP11).

We initiate coverage of PYC with a speculative BUY recommendation and $0.17 valuation. Pro-forma cash balance was ~$84m as at 31 March 2024, providing runway into 2H CY25 to achieve the above-mentioned Phase 1/2 clinical trial readouts. PYC have multiple shots on goal with three highly promising drug candidates for rare diseases. We also see value in the company's internal platform and potential to continually generate differentiated RNA therapeutics for inherited diseases.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is up 15% on guidance upgrade?

Let's find out what is getting investors excited on Tuesday.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

3 reasons why the Sigma Healthcare share price could be a buy

This business has a very exciting outlook.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »